It is widely prospected to be a ground-breaking platform to improve the drug efficacy by delivering the drug to the tumor site and enhancing cellular internalization. Nanotechnology has made remarkable advancement in cancer drug delivery. 7, 8 Due to these facts, there is a pressing need to explore more effective therapeutic strategies for improving treatment efficacy of Gem to combat pancreatic cancer. 5, 6 In addition, it has reported that combination of Gem with other agents only has limited improvements in survival rates. 4 The clinical efficacy of Gem is mainly limited by its metabolic instability and poor cellular uptake, which results in frequent administration of Gem with high dosage, hence ending with serious systemic toxicity. 3 However, its efficacy remains largely unsatisfactory, the 5-year survival rate is only 2%.
#Dynamic light scattering protocol Pc#
Gemcitabine (Gem, 20, 20-difluorodeoxycytidine, dFdC), a pyrimidine analogue, is the first line and the gold standard drug for all stages of advanced PC since 1997.
1 As only less than 20% of PC patients can benefit from surgery treatment, 2 chemotherapy is therefore a mainstream treatment against this cancer. It has an overall survival rate less than 10% and a median survival less than 6 months. Pancreatic cancer (PC) is one of the most lethal and devastating human cancers. Keywords: gemcitabine, amphiphilic dendrimer, self-assembling, pancreatic cancer, anticancer candidate This study also underlines the potential use of self-assembling amphiphilic dendrimer-based nanotechnology for improving drug efficacy as well as reducing drug toxicity. Moreover, the nanodrug displayed greatly reduced adverse effects and satisfactory biocompatibility.Ĭonclusion: Benefiting the advantageous features of both amphiphilic dendrimers and nanotechnology-based drug delivery, this gemcitabine nanosystem constitutes a promising therapeutic candidate for pancreatic cancer treatment.
#Dynamic light scattering protocol free#
Finally, the gemcitabine nanoformulation displayed more potent anticancer activity compared to free gemcitabine both in vitro and in vivo. With the features of small size, stable formulation and pH-responsive drug release, the obtained gemcitabine nanoformulation could effectively accumulate in tumor site and rapid uptake in cells. This dendrimer-based gemcitabine nanoformulation reported here possess a high drug loading of 33%. Results: We developed a novel nanodrug delivery system of gemcitabine using amphiphilic dendrimer. Subsequently, the size, morphology, drug loading, stability, drug release profiles, cell uptake, toxicity, the anticancer activity and in vivo distribution of the new developed gemcitabine delivery system were systematically evaluated by different technical methods, including transmission electron microscopy (TEM), dynamic light-scattering (DLS), ultraviolet spectrophotometer, flow cytometry, in vivo imaging system etc. Then the aliphatic gemcitabine prodrug was encapsulated into the small amphiphilic dendrimer by film dispersion method, resulting in a novel nanodrug delivery system. Methods: An aliphatic gemcitabine prodrug and a small amphiphilic dendrimer were synthesized and characterized by high resolution mass spectrometry (HRMS) as well as nuclear magnetic resonance (NMR). To enhance the clinical efficacy of gemcitabine, we constructed a novel nanodrug delivery system based on amphiphilic dendrimers and aliphatic gemcitabine prodrug. However, the anticancer efficacy is severely limited by its instability and poor cellular uptake. Purpose: Gemcitabine is the first line and the gold standard drug for pancreatic cancer. *These authors contributed equally to this workĬorrespondence: Mei Cong, School of Pharmacy, Xinxiang Medical University, Xinxiang, 453003, People’s Republic of China, Tel +86 0373 3029879, Fax + 86 0373 3029879, Email Weidong Zhao, 1, 2, * Shaoyou Yang, 3, * Chunxiao Li, 1, 2 Feifei Li, 1, 2 Houjun Pang, 3 Guangling Xu, 1, 2 Yuxin Wang, 3 Mei Cong 3ġHenan Key Laboratory of Immunology and Targeted Drugs, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, People’s Republic of China 2Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, Xinxiang Medical University, Xinxiang, People’s Republic of China 3School of Pharmacy, Xinxiang Medical University, Xinxiang, People’s Republic of China
0 kommentar(er)
